Abdul M Oseini1, Lewis R Roberts. 1. Miles and Shirley Fiterman Center for Digestive Diseases College of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA. roberts.lewis@mayo.edu
Abstract
BACKGROUND: Hepatocellular carcinoma (HCC) develops most often in a background of chronic inflammatory liver injury from viral infection or alcohol use. Most HCCs are diagnosed at a stage at which surgical resection is not feasible. Even in patients receiving surgery rates of recurrence and metastasis remain high. There are few effective HCC therapies and hence a need for novel, rational approaches to treatment. Platelet derived growth factor receptor-alpha (PDGFR-alpha) is involved in tumor angiogenesis and maintenance of the tumor microenvironment and has been implicated in development and metastasis of HCC. OBJECTIVE: To examine PDGFR-alpha as a target for therapy of HCC and explore opportunities and strategies for PDGFR-alpha inhibition. METHODS: A review of relevant literature. RESULTS/ CONCLUSIONS: Targeted inhibition of PDGFR-alpha is a rational strategy for prevention and therapy of HCC.
BACKGROUND:Hepatocellular carcinoma (HCC) develops most often in a background of chronic inflammatory liver injury from viral infection or alcohol use. Most HCCs are diagnosed at a stage at which surgical resection is not feasible. Even in patients receiving surgery rates of recurrence and metastasis remain high. There are few effective HCC therapies and hence a need for novel, rational approaches to treatment. Platelet derived growth factor receptor-alpha (PDGFR-alpha) is involved in tumor angiogenesis and maintenance of the tumor microenvironment and has been implicated in development and metastasis of HCC. OBJECTIVE: To examine PDGFR-alpha as a target for therapy of HCC and explore opportunities and strategies for PDGFR-alpha inhibition. METHODS: A review of relevant literature. RESULTS/ CONCLUSIONS: Targeted inhibition of PDGFR-alpha is a rational strategy for prevention and therapy of HCC.
Authors: Franziska Mußbach; Petra Henklein; Martin Westermann; Utz Settmacher; Frank-D Böhmer; Roland Kaufmann Journal: J Cancer Res Clin Oncol Date: 2014-11-06 Impact factor: 4.553
Authors: Valerie N Barton; Andrew M Donson; Bette K Kleinschmidt-DeMasters; Diane K Birks; Michael H Handler; Nicholas K Foreman Journal: Brain Pathol Date: 2009-09-10 Impact factor: 6.508